Dark

Check out our Dark Pool Levels

ANPC
AnPac Bio-Medical Science Co., Ltd.
stock NASDAQ

Inactive

May 19, 2023

4.37USD-5.409%(-0.25)35,704

Pre-market

0.00USD-100.000%(-4.62)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

07:30AM EST Leading US Market Analysis and Research Firm Ranked AnPac Bio GlobeNewswire Inc

Jan 24, 2022

05:00PM EST AnPac Bio Receives NASDAQ Notification Regarding Minimum Market GlobeNewswire Inc

Jan 4, 2022

07:32AM EST AnPac Bio Class III Medical Device Passes NMPA Registration Tests And Will Start Clinical Trial In Q1, 2022 Benzinga

07:30AM EST AnPac Bio Class III Medical Device Passes Extensive NMPA GlobeNewswire Inc

Dec 10, 2021

07:34AM EST AnPac Bio-Medical Science Highlights Joint Technical Paper On Novel Cancer Differentiation Analysis Technology For Co.'s Multi-Cancer Screening With Institutions Was Accepted, Published Online In 'Expert Review Of Molecular Diagnostics' Benzinga

07:30AM EST Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology GlobeNewswire Inc

Nov 26, 2021

01:30PM EST AnPac Bio Reports Nine Months Ended September 30, 2021, Same GlobeNewswire Inc

Nov 11, 2021

03:19AM EST CORRECTION -- Anpac Bio, USA GlobeNewswire Inc

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

Nov 9, 2021

05:42PM EST AnPac Bio-Medical Science Commences Offering Of ADSs, No Size Disclosed Benzinga

Oct 4, 2021

07:33AM EDT AnPac Bio Announces Study Shows Strong Correlation Between CDA Score And Risk Of Cancer And Diseases Benzinga

07:30AM EDT AnPac Bio Study Shows Strong Correlation between CDA Score and GlobeNewswire Inc

Oct 1, 2021

07:31AM EDT AnPac Bio-Medical Science 1H Sales $1.4M, Up 128.5% YoY Benzinga

07:30AM EDT AnPac Bio-Medical Science Co., Ltd. (AnPac Bio, the Company or we) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2021. GlobeNewswire Inc

Sep 30, 2021

04:07PM EDT AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value Of Listed Securities Deficiency Benzinga

04:05PM EDT AnPac Bio Receives NASDAQ Notification Regarding Minimum Market GlobeNewswire Inc

Sep 7, 2021

12:19PM EDT BioMedNewsBreaks AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase In Subsidiary Holding Benzinga

Sep 3, 2021

04:15PM EDT AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai GlobeNewswire Inc

Aug 30, 2021

07:30AM EDT AnPac Bios USA Laboratory Receives Accreditation GlobeNewswire Inc

Aug 23, 2021

07:32AM EDT AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration for Registration Testing of Its Multi-Cancer CDA Device Benzinga

07:30AM EDT AnPac Bio Successfully Completes Major PreClinical Study, Files GlobeNewswire Inc

Aug 17, 2021

07:33AM EDT Anpac Bio-Medical Science Appoints Dr Sunil Pandit As US CEO, Effective Aug. 16 Benzinga

07:30AM EDT AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO GlobeNewswire Inc

Aug 10, 2021

12:08PM EDT AnPac Bio-Medical Services Granted U.S. Patent Titled 'Micro-devices for disease detection' Benzinga

Aug 5, 2021

08:02AM EDT AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solutions Benzinga

07:30AM EDT AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation GlobeNewswire Inc

Jul 23, 2021

07:30AM EDT AnPac Bio Announces Appointment of New Independent Director GlobeNewswire Inc

Jul 21, 2021

06:30AM EDT AnPac Bio Began Generating Contract Medical Device R&D Revenue GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

07:13AM EDT AnPac Bio Stock Gains On Robust Growth In Commercial Testing Volume In Q2 Benzinga

06:33AM EDT AnPac Bio-Medical Science Reports H1'21 Paid Customers, Testing Volume Up ~110% Year Over Year; Q2 Paid Tests Up 280% Quarter Over Quarter Benzinga

06:30AM EDT AnPac Bio Pre-announces that During First Half 2021, Total GlobeNewswire Inc

Jun 18, 2021

10:40AM EDT Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings Benzinga

09:22AM EDT AnPac Bio-Medical Stock Moves Higher On First Disease Treatment US Patent Benzinga

06:31AM EDT AnPac Bio-Medical Science Reports Patent Grant For Novel Device Structures, Methods To Modify Biological Samples For Treatment Purposes Benzinga

06:30AM EDT AnPac Bios First Disease Treatment Patent GlobeNewswire Inc

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

06:37AM EDT AnPac Bio-Medical Science Q1 EPS $(0.37), Sales $300.00K Benzinga

06:30AM EDT AnPac Bio Reports Strong First Quarter in 2021, with 137.2% GlobeNewswire Inc

May 25, 2021

08:15AM EDT AnPac Bio Shares Jump on Cancer Treatment Technology Related Joint Venture Benzinga

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

06:34AM EDT AnPac Bio-Medical Announces Novel Cancer Treatment Technology And Product Joint Venture Benzinga

06:30AM EDT AnPac Bio Launches Novel Cancer Treatment Technology and Product GlobeNewswire Inc

Apr 30, 2021

04:45PM EDT AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 GlobeNewswire Inc

08:19AM EDT AnPac Bio Reports FY 2020 Revs RMB20.5M Benzinga

08:00AM EDT AnPac Bio-Medical Science Co., Ltd. (AnPac Bio, the Company or we) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its annual financial results for the year ended December 31, 2020. GlobeNewswire Inc

04:12AM EDT Earnings Scheduled For April 30, 2021 Benzinga

Apr 16, 2021

04:21PM EDT AnPac Bio Reports Q1 Paid For CDA-Based Cancer Testing Of 5,439 Up Roughly 130% YoY Benzinga

04:15PM EDT AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing GlobeNewswire Inc

Mar 10, 2021

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

Mar 9, 2021

02:31PM EST Mid-Afternoon Market Update: Nasdaq Surges Over 500 Points; INVO Bioscience Shares Spike Higher Benzinga

12:19PM EST Mid-Day Market Update: Gold Rises Over 2%; ACADIA Pharmaceuticals Shares Plunge Benzinga

10:26AM EST AnPac Bio-Medical Science Co., Ltd. (ANPC) shares are trading higher on Tuesday morning as the biotechnology company focused on early cancer screening and detection said it has completed evaluations of a new generation multi-cancer detection sensor named CDA Pro Sensor. RTTNews

10:18AM EST Mid-Morning Market Update: Markets Open Higher; Dicks Sporting Goods Profit Beats Views Benzinga

09:16AM EST UPDATE: AnPac Bio Says 'sensor cost has been reduced by ~ 137% and both cancer detection sensitivity and specificity reached over 95% in a retrospective clinical sample test' Benzinga

09:16AM EST AnPac Bio Says Has Developed And Completed Evaluations For Its CDA Pro Cancer Detection Sensor Benzinga

07:30AM EST AnPac Bio Developed and Completed Evaluations ofNew GlobeNewswire Inc

Mar 5, 2021

04:35PM EST AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement GlobeNewswire Inc

Feb 24, 2021

11:54AM EST AnPac Bio-Medical Science Co Shares Move Higher; Co Granted EU Patent Titled 'MICRO-DEVICES FOR IMPROVED DISEASE DETECTION' Benzinga

Feb 8, 2021

07:12AM EST AnPac Bio-Medical Science Co Says China's NMPA Approved Starting Registration Testing Of Co's Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility) Benzinga

07:00AM EST Chinas NMPA Approved Starting of Registration GlobeNewswire Inc

Feb 1, 2021

07:35AM EST AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection Benzinga

07:30AM EST AnPac Bio Granted a New US patent on Novel Medical Device for GlobeNewswire Inc

Dec 21, 2020

10:51AM EST IPOs Drive Day Trading Profits In The Final Weeks Of 2020 Benzinga

Dec 14, 2020

02:33PM EST Mid-Afternoon Market Update: Dow Turns Negative; Arvinas Shares Spike Higher Benzinga

02:32PM EST Mid-Afternoon Market Update: Dow Turns Lower; Arvinas Shares Spike Higher Benzinga

12:08PM EST Mid-Day Market Update: Nasdaq Rises 1.1%; Aerpio Pharmaceuticals Shares Plummet Benzinga

10:14AM EST Mid-Morning Market Update: Markets Open Higher; FDA Authorizes Pfizer-BioNTech Covid-19 Vaccine Benzinga

10:09AM EST Shares of AnPac Bio-Medical Science Co., Ltd. (ANPC), a biotechnology company, are surging almost 83 percent or $3.49 in Monday's morning trade at $7.71. RTTNews

07:41AM EST AnPac Bio Says 'Initial results indicated that AnPac Bio CDA technology is capable of providing meaningful information while also screening out pre-cancer diseases' Benzinga

07:33AM EST AnPac Bio-Medical Science Announces 'Significant Progress' In Detecting Pre-Cancer Diseases Benzinga

07:30AM EST AnPac Bio Makes Significant Progress in Detecting Pre-cancer GlobeNewswire Inc

Dec 4, 2020

04:01PM EST Anpac Bio Announces Change of Auditor GlobeNewswire Inc

Nov 25, 2020

02:35PM EST Mid-Afternoon Market Update: Nasdaq Gains 50 Points; RenalytixAI Shares Spike Higher Benzinga

12:32PM EST Mid-Day Market Update: Gap Falls on Earnings Miss; AnPac Bio-Medical Science Shares Climb Benzinga

11:01AM EST Why These 3 Health Care Stocks Are Trading Higher Today Benzinga

10:14AM EST Mid-Morning Market Update: Markets Open Lower; Deere Beats Q4 Views Benzinga

10:13AM EST Shares of biotechnology company AnPac Bio-Medical Science Co., Ltd. (ANPC) are surging more than 90% Wednesday morning after the company reported strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. RTTNews

07:31AM EST AnPac Bio Sees FY20 Sales $3M-$3.3M vs $1.99M Est. Benzinga

07:30AM EST AnPac Bio Sets Record Test Volume in Q3, and Forecasts 100% GlobeNewswire Inc

Nov 16, 2020

04:01PM EST Anpac Bio Announces Appointment of New Independent Director GlobeNewswire Inc

Nov 10, 2020

07:33AM EST AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing Benzinga

07:30AM EST AnPac Bio US Completes COVID-19 Antibody Test Verification and GlobeNewswire Inc

Nov 6, 2020

09:17AM EST Tricky Trading Through The Election Benzinga

Nov 2, 2020

10:18AM EST Mid-Morning Market Update: Markets Open Higher; Este Lauder Profit Tops Views Benzinga

10:16AM EST Shares of nano-cap company AnPac Bio-Medical Science Co., Ltd. (ANPC) are gaining over 16% on Monday morning after the biotech company announced that its investee company in China received COVID-19 nucleic acid test certification. RTTNews

07:41AM EST AnPac Bio's Investee Company in China Received COVID-19 Nucleic Acid Test Certification and Began Volume Tests and Collaborations with AnPac Bio Benzinga

07:30AM EST AnPac Bios Investee Company in China Received GlobeNewswire Inc

Oct 26, 2020

06:45AM EDT Anpac Bio Completes Over 200,000 Biophysics Based Cancer Detection GlobeNewswire Inc

Oct 7, 2020

07:24AM EDT AnPac Bio Obtains Three Grants And One Rental Award From Various Local Authorities In China RTTNews

07:04AM EDT AnPac Bio to Receive Up To $8M Dollar Grants and Award for R&D, Product Commercialization, and Milestone Achievements Benzinga

07:00AM EDT AnPac Bio to Receive Up To USD $8 Million Dollar Grants and Award GlobeNewswire Inc

Oct 1, 2020

07:37AM EDT AnPac Bio Announces Equity Investment From Keystone Capital Partners For Up To $7M Benzinga

07:35AM EDT AnPac Bio-Medical Science Enters Deal With Keystone Capital For Preferred Stock Investment Of $7 Mln RTTNews

07:30AM EDT AnPac Bio Announces Equity Investment from Keystone Capital GlobeNewswire Inc

Sep 23, 2020

08:15AM EDT Tiger Asia Intelligence reiterates a Buy rating on AnPac Bio, Ltd (NASDAQ:ANPC) PR Newswire

Sep 15, 2020

07:08AM EDT AnPac Bio Says In Mid Aug. Entered Immunology Testing Contract With Beijing Yuan Jian Health Benzinga

07:00AM EDT AnPac Bio Receives Major Immunology Testing Contract GlobeNewswire Inc

Sep 10, 2020

06:58AM EDT AnPac Bio Reports Total Revenues Were RMB4.1 Million Or US$0.6 Million For The First Six Months Of 2020, An Increase Of 3.4% From RMB$3.9 Million For The First Six Months Of 2019. Benzinga

Sep 4, 2020

07:34AM EDT AnPac Bio Reports Positive Results From Multi-Year Lung Cancer Prognosis And Recurrence Clinical Study RTTNews

07:33AM EDT AnPac Bio-Medical Science Says 'Initial results from the study indicate that CDA technology could act as a viable tool for measuring and evaluating (1) lung cancer treatment and efficacy and (2) recurrence following remission.' Benzinga

07:32AM EDT AnPac Bio Announces Results From A Multi-Year Lung Cancer Prognosis And Recurrence Clinical Study Benzinga

07:30AM EDT AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer GlobeNewswire Inc

Aug 24, 2020

07:35AM EDT AnPac Bio Philadelphia Lab Gains US CLIA Lab Certification Benzinga

Aug 11, 2020

07:30AM EDT AnPac Bio Opens US Philadelphia Lab Operations GlobeNewswire Inc

Aug 7, 2020

11:32AM EDT Shares of AnPac Bio-Medical Science Co., Ltd. (ANPC) are up over 45% on Friday morning. RTTNews

10:12AM EDT Mid-Morning Market Update: Markets Open Lower; US Unemployment Rate Drops To 10.2% Benzinga

07:35AM EDT AnPac Bio-Medical Science Reports Co. Has Been Validating The Approved Coronavirus Test For Commercial Use In Its San Jose, California Lab Since Q2, Sees Validation Completion In H2'20 Benzinga

07:30AM EDT AnPac Bio Validating Approved COVID-19 Antibody Test GlobeNewswire Inc

Aug 4, 2020

07:50AM EDT AnPac Bio Announces Preliminary Results From Prospective Trials of Co.'s Bio's Cancer Differentiation Analysis Benzinga

07:30AM EDT AnPac Bio Announces Preliminary Results From Prospective Trials GlobeNewswire Inc

Jul 29, 2020

08:28AM EDT AnPac Bio Completes Over 180K CDA-Based Cancer Risk Assessment Tests Benzinga

08:26AM EDT AnPac Bio-Medical Science Co., Ltd. (AnPac Bio, the Company or we) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over 180,000 Cancer Differentiation Analysis (CDA) based tests as of July 15, 2020. GlobeNewswire Inc

Jul 13, 2020

08:41AM EDT AnPac Bio Completed 1st Half Year with Increased ASP and Revenue GlobeNewswire Inc

Share